Download Files:
Lasofoxifene (tartrate)
$66 – $343
Products Details
Product Description
– Lasofoxifene (CP-336156) tartrate is an orally active and selective estrogen receptor modulator (SERM)[1]. Lasofoxifene tartrate exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene tartrate can be used for the research of breast cancer and postmenopausal osteoporosis[1][2].
Web ID
– HY-A0038
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Molecular Formula
– C32H37NO8
Citations
– Gynecol Oncol. 2019 Jul;154(1):199-206.|Mol Cancer Ther. 2020 Jul;19(7):1395-1405.|NPJ Breast Cancer. 2022 Dec 14;8(1):130.
References
– [1]Andreano KJ, et al. The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor. Mol Cancer Ther. 2020 Jul. 19(7):1395-1405. |[2]Lainé M, et al. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res. 2021 May 12. 23(1):54. |[3]Andersson A, et al. Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis. Rheumatology (Oxford). 2016 Mar;55(3):553-63.
CAS Number
– 190791-29-8
Molecular Weight
– 563.64
Compound Purity
– 99.92
SMILES
– OC1=CC=C2[C@@H](C3=CC=C(OCCN4CCCC4)C=C3)[C@@H](C5=CC=CC=C5)CCC2=C1.O=C(O)[C@@H](O)[C@H](O)C(O)=O
Clinical Information
– Launched
Research Area
– Endocrinology; Cancer
Solubility
– DMSO : 83.33 mg/mL (ultrasonic)
Target
– Estrogen Receptor/ERR
Pathway
– Vitamin D Related/Nuclear Receptor
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
